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UNDERSTANDING LEUKEMIA 
The role of CYP450 on Childhood Acute Lymphoblastic Leukemia  
Gemma Llargués i Sistac  | Genetics Degree,  Universitat Autònoma de Barcelona (UAB), 2014 
 The aim of the present poster is to review the current knowledge about the known CYP 450 polymorphisms that alter response to drugs and 
treatment outcome of those pediatric patients with Acute Lymphoblastic Leukemia. 
Childhood ALL
• ALL is the most common pediatric malignancy, and results from a multiple-step model of carcinogenesis.  
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• Cure rates have improved from less than 10% in the 1960s to 90% nowadays 
- Cancer of rapid progression 
 
- Accumulation of immature lymphocytes 
 
- 27% of all pediatric cancers   
 
Cytochrome P450 (CYPs) 
The therapy for ALL consists of drugs with 
highly toxic profile     
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ADVERSE EFFECTS 
Direct toxicity produced in healthy tissue 
         main cause of morbidity and mortality 
Not all children treated respond equally to drugs 
  
Seeks to define the differences between 
patients associated with treatment failure  
Pharmacogenetics 
Genetic variations can modulate overall effect 
of therapy  
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Genetic polymorphisms modulate the efficacy of 
antileukemic agents and clinical outcome of ALL. 
• enzymes responsible for most phase I reactions 
 
• super family of mono-oxygenases                “activanting” molecular oxigen  
 
• capable of catalyzing the oxidative biotransformation of xenobiotics 
 
• 57 genes and 58 pseudogenes         12 enzymes belonging to the 1, 2 and 3 CYP-families effectuate the metabolism of the majority of drugs 
 
• highly polymorphic   
 
           
 
drug efficacy is affected by a number of non-
genetic and genetic influences, like SNPs in genes 
expressing enzymes involved in: 
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CYP1A1 
      procarcinogen bioactivation 
             induced by PAHs  
CYP2 gene family 
CYP2B6 CYP2E1 CYP2D6 
             largest family of CYPs in humans 
several of the most important drug metabolizing CYP 
CYP3 gene family 
CYP3A4 
     the most well-studied CYPs in ALL 
CYP3A induction increases drug clearance 
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● multidisciplinary research is needed to understand both the biology of the disease and the host in order to prevent drug toxicity and adverse effects 
● CYP enzymes have an important role in metabolizing drugs administrated to pediatric patients with ALL 
● there is still a lack of evidence in regard to the true genetic contribution of CYP variants to the drug metabolism genotype 
● further evaluation of the genetic variants reported in this project is needed in order to unequivocally establish their association with pediatric ALL 
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